Are you a healthcare professional?
Oral Dexpramipexole. Our Novel Candidate for
An Uncommon Approach to a Common Respiratory Disorder
of all patients suffering with severe asthma have elevated numbers of eosinophils in their blood and lungs.
High levels of eosinophils increase the risk of asthma attacks and lung damage.
At present, the only treatments for eosinophilic asthma come in the form of injections or infusions.
Dexpramipexole is an experimental drug shown to block eosinophils from maturing in the bone marrow, and is under investigation as a potential treatment for eosinophilic asthma.
Ongoing clinical research on the role of eosinophils in asthma has already created benefits for many patients.
Our Goal is to demonstrate the safety and effectiveness of dexpramipexole
Phase 2 trial data will be reported soon. We welcome you to follow our progress.
Discover this News
Knopp’s pipeline consists of investigational drug products that have not been approved by the U.S. Food and Drug Administration. These investigational drug products are undergoing clinical study to verify their safety and effectiveness.